01BLIND PURCHASE
Independent samples, named labs
We buy anonymously through the same retail channels any researcher would use. Suppliers are not notified that a sample is ours. The lab is named on every assay page. No cherry-picked batches.
◉ Issue 04 · 2026/Batch report 04·26·B/N = 27
The science, and the material, both get tested.
Open Assay is the peptide research platform where the education is rigorous, the testing is independent, and every supplier recommendation is backed by published data — not affiliate economics.
51
Peptides
covered
27
Samples
independently tested
12
Suppliers
monitored
57
Primary-lit
citations
Research use onlyOpen Assay publishes independent analytical data and primary-literature references. Nothing here constitutes medical advice, diagnosis, or dosing guidance. Jurisdictional restrictions apply.READ FIRST →
§ 01
What makes this different
03 / PRINCIPLES
02PRIMARY LITERATURE
Every claim has a PMID
We do not write 'studies show.' We tell you which study, what it actually measured, how many subjects, and what its limitations were. Negative trials get equal space to mechanistic papers.
03PUBLIC FAILURES
Rankings move with data
Test outcomes are published — including failures against affiliate partners. Rankings are set before affiliate relationships are negotiated and cannot be bought. Supplier rebuttals are recorded on the assay page.
§ 03 / TRUST
Read before you trust anyone — including us.
Our methodology page explains exactly how we source samples, which labs we use, what thresholds define pass/fail, and how we resolve disputes. If you wouldn't accept these standards, don't trust our data. Our editorial policy covers the firewall between affiliate revenue and ranking.
§ 02
Recent work
EDITORIAL
Feature
Evidence vs. Claims
A candid audit of the gap between peer-reviewed peptide science and popular social-media narratives. Case studies in BPC-157 single-lab dominance, MOTS-c mouse healthspan extrapolation, SS-31's negative Phase 3, and Epitalon.
Reference
The evidence-tier scale
Every peptide on the site is graded on a four-tier scale from FDA-approved Phase-3 RCTs down to speculative in-vitro claims. Here is what each tier means and how a peptide moves between them.